Dr. Iris Zemzoum new managing director of Janssen-Cilag

12.12.2012 17:09

The research-based drug manufacturer Janssen will in future be led by Dr. Iris Zemzoum led. The licensed doctor took up her position as Managing Director at the company headquarters in Neuss on December 1st. She was most recently managing director of Bristol Myers Squibb in Switzerland.

After Kris Sterkens moved to the European corporate level in the spring, Janssen's business was most recently managed by Hans Wormann, Director Therapeutic Value Management, who will continue to be part of the German management.

“As a doctor, research is very important to me. Janssen, the subsidiary of the health care group Johnson & Johnson, has been known to me since my studies: the company, with around 800 employees in the office and in the field, has been one of the leading pharmaceutical manufacturers in the world for more than 50 years thanks to its innovative products in various indications Germany,” says Zemzoum.

The doctor received her doctorate from the Friedrich-Alexander University of Erlangen-Nuremberg and began her career at the women's clinic at the Rechts der Isar Clinic at the Technical University of Munich (TUM. In 2003 she moved to pharmaceutical research at the pharmaceutical company Bristol-Myers-Squibb (BMS). Both in In both the medical and marketing sectors, Zemzoum was responsible for products and therapeutic areas in oncology, hematology and virology. Zemzoum worked in Munich, Brussels and Paris, where she also completed an Executive MBA at the INSEAD business school in Fontainebleau (France) in 2008 In 2010 she moved to Switzerland, where as managing director she took responsibility for over 100 employees and, as a member of the board of VIPS (Association of Swiss Pharmaceutical Companies), realigned the company with a customer-centric strategy.